National Clinical Trial Network Designates St. Luke’s a High Performing Site
February 02, 2018
Bethlehem, PA – The National Clinical Trials Network has awarded St. Luke’s University Health Network $30,000 as part of its “High Performing Site Initiative.” The Trials Network is a National Cancer Institute program that provides funds and other support to cancer research organizations to conduct national clinical trials.
“We are very honored to have been selected to participate in the High Performing Site Initiative for the second year in a row,” says St. Luke’s Senior Network Director of Clinical Trials and Research Tracy Butryn, MS, CCRP, CHRC. “The grant recognizes our commitment to bringing leading edge treatments to our patients through our participation in clinical trials at a national level, as well as our high quality standards for clinical trial conduct.”
St. Luke’s participated in 16 NCI-sponsored clinical trials during this year’s award period from March 1, 2016 through Feb. 28, 2017. The HPSI compensates high-performing sites recognizing that the “per-case management funding” provided by the NCI is significantly lower than the actual costs incurred by the member institutions/sites to participate on a trial. The amount of the award was based on St. Luke’s overall Trials Network participation, evidence of integration activities and data quality within the program. This award will be used for infrastructure support to cover costs related to continued successful participation in national clinical trials at St. Luke’s.
The St. Luke’s Clinical Trials Office is the clinical and administrative shared resource for the conduct and management of sponsored clinical research across St. Luke’s. The Trials Office allows a centralized and streamlined approach to all sponsored-research conducted throughout the Network by integrating both the clinical operational team and the research administration team into one centralized office. This infrastructure ensures that both the clinical and administrative operations involved in clinical research are compliant with all regulations and policies, and that the workflow between sponsors, physicians, clinical support staff and other ancillary departments is streamlined and efficient.
St. Luke’s participates in more than 145 clinical trials, enrolling an average of 200+ patients in any given year. To learn more about clinical trials at St. Luke’s, visit www.research.slhn.org/Clinical-Trials.
Media Contact:
Sam Kennedy, Corporate Communications Director, 484-526-4134, samuel.kennedy@sluhn.org
About St. Luke’s
Founded in 1872, St. Luke’s University Health Network is a fully integrated, regional, non-profit network providing services at nine hospitals and nearly 300 outpatient sites. With annual net revenue of $1.7 billion, the network’s service area includes 10 counties: Lehigh, Northampton, Carbon, Schuylkill, Bucks, Montgomery, Berks and Monroe counties in Pennsylvania and Warren and Hunterdon counties in New Jersey. Dedicated to advancing medical education, St. Luke’s is a major teaching hospital – the only one in the Greater Lehigh Valley. In partnership with Temple University, St. Luke’s created the region’s first and only regional medical school campus. It also operates the nation’s longest continuously operating School of Nursing, established in 1884, and 23 fully accredited graduate medical educational programs with 189 residents. Repeatedly, including 2017, St. Luke’s earned Truven’s 100 Top Major Teaching Hospital and 50 Top Cardiovascular Program designations, in addition to other honors for clinical excellence. St. Luke’s, utilizing the EPIC electronic medical record (EMR) system, is a multi-year recipient of the Most Wired award recognizing the breadth of St. Luke’s information technology applications such as telehealth, online scheduling and online pricing information. St. Luke’s is also recognized as one of the state’s lowest cost providers.
Latest News
November 19, 2024
This Pediatric Experience Went Above and Beyond
November 16, 2024
SLUHN Hospitals Earn Straight A Grades for Safety
November 14, 2024